P/E at 60.74 vs Industry's 67.63: What the Data Shows for Apollo Hospitals Enterprise Ltd.

Valuation Picture: Discount Despite Large-Cap Status

Apollo Hospitals Enterprise Ltd. trades at a P/E multiple of 60.74, which is approximately 10.2% below the hospital sector’s average of 67.63. This discount is intriguing given the company’s large-cap stature with a market capitalisation of ₹1,28,126.51 crores. The valuation gap suggests that investors may be pricing in either a more cautious outlook on near-term earnings growth or a premium on sector peers that have outperformed recently. The sector’s elevated P/E reflects optimism around healthcare demand and innovation, yet Apollo Hospitals appears to be valued more conservatively within this context — previously rated Strong Buy, what is Apollo Hospitals’ current rating?

Performance Across Timeframes: Consistent Outperformance

Examining returns over multiple periods reveals a consistent pattern of outperformance relative to the Sensex. Over the past year, Apollo Hospitals has gained 15.98%, while the Sensex declined by 8.93%. Year-to-date, the stock’s 26.53% rise contrasts sharply with the Sensex’s 12.27% fall. Even over longer horizons, the stock’s 3-year return of 78.69% and 5-year return of 74.92% significantly exceed the Sensex’s 13.27% and 24.85%, respectively. The 10-year performance is particularly striking, with a gain of 565.77% compared to the Sensex’s 160.80%. This long-term outperformance underscores the company’s resilience and growth trajectory within the hospital sector.

Shorter-term momentum also remains positive. The stock has advanced 4.99% over the last three months, outperforming the Sensex’s 1.88% decline. The one-month gain of 2.91% and one-week rise of 2.27% further highlight recent strength — is this momentum sustainable or a temporary reprieve?

Moving Average Configuration: Bullish Technical Setup

The technical picture for Apollo Hospitals is notably constructive. The stock is trading above all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This alignment indicates a strong upward trend across both short and long-term horizons. Being close to its 52-week high, just 4.5% shy of ₹9,326.8, the stock’s price action suggests sustained buying interest and positive market sentiment. The consistent trading above these averages typically signals a robust recovery or continuation of an uptrend rather than a fleeting bounce — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context: Hospital Industry Trends

The hospital sector has experienced mixed results recently, with some companies reporting strong earnings growth while others face margin pressures. The sector’s average P/E of 67.63 reflects elevated expectations for healthcare services amid demographic shifts and rising medical expenditure. Within this environment, Apollo Hospitals’ valuation discount may indicate a more cautious market stance or a reflection of company-specific factors. Sector results have been varied, with several stocks posting positive returns, some remaining flat, and others declining. This uneven performance highlights the importance of analysing individual company data rather than relying solely on sector trends.

Rating Reassessment: Previously Strong Buy

On 15 Sep 2026, the rating for Apollo Hospitals Enterprise Ltd. was updated from a previous Strong Buy rating. The Mojo Score stands at 77.0, reflecting a solid overall assessment. This reassessment takes into account the company’s valuation, performance metrics, and technical indicators. The rating change invites investors to consider how the new evaluation aligns with the stock’s current market position and recent trends — should investors in Apollo Hospitals hold, buy more, or reconsider?

Collective Data Insights: Valuation, Performance, and Technicals

Bringing together valuation, performance, and technical data, Apollo Hospitals Enterprise Ltd. presents a compelling profile. The stock’s P/E discount relative to its sector suggests a more measured valuation approach despite its large-cap status. Its consistent outperformance over one, three, and five years, alongside a strong 10-year track record, highlights durable growth. The bullish moving average configuration reinforces the positive momentum, with the stock trading above all major averages and nearing its 52-week high. The recent rating reassessment from Strong Buy reflects these dynamics, signalling a nuanced view of the company’s prospects in a complex sector environment.

Investors weighing the data may ask — how should the current rating influence portfolio decisions?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today